ACCEPT DECLINE
Change Visitor Type

Portfolio

Scancell

Scancell floated on the PLUS stock exchange in September 2008, raising £1.6m, and moved to AIM in July 2010. Oxford Capital sold the majority of its position during 2012.

Scancell was spin-out from Nottingham University which developed and patented a revolutionary therapeutic vaccine technology – the ImmunoBody platform – that overcomes the limitations of many existing therapeutic vaccines. Scancell’s first cancer vaccine, SCIB1, is being developed for the treatment of melanoma and is in Phase I/II clinical trials. The initial results have been highly encouraging and suggest that SCIB1 could have an important future role as first line treatment for patients with resected Stage II or III disease, a key area of unmet medical need for which there are no effective and safe treatment options available.

3
  • UltraSoC strengthens management team with appointment of CFO


    Read more
  • UltraSoC embedded analytics selected to support Wave Computing’s TritonAI 64 IP platform


    Read more

  • News and Views

    The lastest industry news and views
    from our team at Oxford Capital.

    see more
  • The changing face of UK VC: Esther Delignat-Lavaud Rodriguez, investor at Oxford Capital


    Read more
  • Latent Logic moves into new office in Oxford


    Read more
  • Oxford Capital has led a £6.5m series-A funding round for UK-headquartered courier service Weengs.


    Read more
  • Cycle-accurate trace boosts performance optimization capabilities of UltraSoC embedded analytics infrastructure


    Read more